Development of Novel Hybrid Antibiotics for the Treatment of Hospital and Community Acquired Drug Resistant Gram-Negative and Gram-Postitive Bacterial Infections

开发用于治疗医院和社区获得性耐药革兰氏阴性和革兰氏阳性细菌感染的新型混合抗生素

• 批准号: nhmrc : 1005350
• 负责人: Prof David Paterson
• 金额: $ 47.68万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-novel-hybrid-bacterial-infections/109098
• 关键词: Development; Novel; Hybrid; Antibiotics; Treatment

Drug resistant bacteria now pose a serious and growing threat to human health. Many bacteria have developed new resistance mechanisms such that most common antibiotics no longer can protect patients from serious, life-threatening infection. We will modify two existing antibiotics, colistin and carbapenem (a penicillin), to convert it into a more powerful antibiotic that targets resistant bacteria.

耐药细菌现在对人类健康构成严重和日益严重的威胁。许多细菌已经产生了新的耐药机制，使得大多数常见的抗生素不再能够保护患者免受严重的、危及生命的感染。我们将修改两种现有的抗生素，粘菌素和碳青霉烯（青霉素），将其转化为针对耐药细菌的更强大的抗生素。